Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

home / publications / supplements / treatment-of-relapsed-refractory-diffuse-large-b-cell-lymphoma

OncLive® provides updates on the treatment of patients with diffuse large B-cell lymphoma through a Scientific Exchange Workshop.

$Expert Perspectives in the Evolving Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma$

Expert Perspectives in the Evolving Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

September 22nd 2020

Article

Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.

$Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma$

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

September 22nd 2020

Article

Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Kahl on the Utility of Tafasitamab/Lenalidomide in DLBCL

Brad Kahl, MD

July 14th 2020

Video

Brad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.

Dr. Abdulhaq on the Benefits of Chemotherapy-Free Options in DLBCL

Haifaa Abdulhaq, MD

July 14th 2020

Video

Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.

Dr. Flinn on Opportunities for Second-Line Tafasitamab in DLBCL

Ian W. Flinn, MD, PhD

July 14th 2020

Video

Ian W. Flinn, MD, PhD, discusses the opportunity for second-line tafasitamab (MOR208, formerly Xmab®5574) as a palliative treatment of patients with diffuse large B-cell lymphoma.